SEARCH

SEARCH BY CITATION

References

  • 1
    Uchiyama T (1997) Human T cell leukemia virus type I (HTLV-I) and human diseases. Annu Rev Immunol 15, 1537.
  • 2
    Yoshida M (2010) Molecular approach to human leukemia: isolation and characterization of the first human retrovirus HTLV-1 and its impact on tumorigenesis in adult T-cell leukemia. Proc Jpn Acad Ser B Phys Biol Sci 86, 117130.
  • 3
    Yasunaga J & Matsuoka M (2007) Leukaemogenic mechanism of human T-cell leukaemia virus type I. Rev Med Virol 17, 301311.
  • 4
    Jacobson S, Shida H, McFarlin DE, Fauci AS & Koenig S (1990) Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature 348, 245248.
  • 5
    Bangham CR (2008) HTLV-1 infection: role of CTL efficiency. Blood 112, 21762177.
  • 6
    Kozako T, Arima N, Toji S, Masamoto I, Akimoto M, Hamada H, Che XF, Fujiwara H, Matsushita K, Tokunaga M et al. (2006) Reduced frequency, diversity, and function of human T cell leukemia virus type 1-specific CD8+ T cell in adult T cell leukemia patients. J Immunol 177, 57185726.
  • 7
    Kozako T, Yoshimitsu M, Fujiwara H, Masamoto I, Horai S, White Y, Akimoto M, Suzuki S, Matsushita K, Uozumi K et al. (2009) PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia 23, 375382.
  • 8
    Ohashi T, Hanabuchi S, Kato H, Tateno H, Takemura F, Tsukahara T, Koya Y, Hasegawa A, Masuda T & Kannagi M (2000) Prevention of adult T-cell leukemia-like lymphoproliferative disease in rats by adoptively transferred T cells from a donor immunized with human T-cell leukemia virus type 1 Tax-coding DNA vaccine. J Virol 74, 96109616.
  • 9
    Albert ML, Sauter B & Bhardwaj N (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 8689.
  • 10
    Kawakami Y, Fujita T, Kudo C, Sakurai T, Udagawa M, Yaguchi T, Hasegawa G, Hayashi E, Ueda Y, Iwata T et al. (2008) Dendritic cell based personalized immunotherapy based on cancer antigen research. Front Biosci 13, 19521958.
  • 11
    Ikehara Y, Niwa T, Biao L, Ikehara SK, Ohashi N, Kobayashi T, Shimizu Y, Kojima N & Nakanishi H (2006) A carbohydrate recognition-based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle. Cancer Res 66, 87408748.
  • 12
    Shimizu Y, Takagi H, Nakayama T, Yamakami K, Tadakuma T, Yokoyama N & Kojima N (2007) Intraperitoneal immunization with oligomannose-coated liposome-entrapped soluble leishmanial antigen induces antigen-specific T-helper type immune response in BALB/c mice through uptake by peritoneal macrophages. Parasite Immunol 29, 229239.
  • 13
    Takagi H, Furuya N & Kojima N (2007) Preferential production of IL-12 by peritoneal macrophages activated by liposomes prepared from neoglycolipids containing oligomannose residues. Cytokine 40, 241250.
  • 14
    Ikehara Y, Shiuchi N, Kabata-Ikehara S, Nakanishi H, Yokoyama N, Takagi H, Nagata T, Koide Y, Kuzushima K, Takahashi T et al. (2008) Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells. Cancer Lett 260, 137145.
  • 15
    Matsui M, Shimizu Y, Kodera Y, Kondo E, Ikehara Y & Nakanishi H (2010) Targeted delivery of oligomannose-coated liposome to the omental micrometastasis by peritoneal macrophages from patients with gastric cancer. Cancer Sci 101, 16701677.
  • 16
    Fukasawa M, Shimizu Y, Shikata K, Nakata M, Sakakibara R, Yamamoto N, Hatanaka M & Mizuochi T (1998) Liposome oligomannose-coated with neoglycolipid, a new candidate for a safe adjuvant for induction of CD8+ cytotoxic T lymphocytes. FEBS Lett 441, 353356.
  • 17
    Sugimoto M, Ohishi K, Fukasawa M, Shikata K, Kawai H, Itakura H, Hatanaka M, Sakakibara R, Ishiguro M, Nakata M et al. (1995) Oligomannose-coated liposomes as an adjuvant for the induction of cell-mediated immunity. FEBS Lett 363, 5356.
  • 18
    Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W Jr, O’Mahony D, Janik JE, Bittencourt AL, Taylor GP et al. (2009) Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol 27, 453459.
  • 19
    Uozumi K (2010) Treatment of adult T-cell leukemia. J Clin Exp Hematop 50, 925.
  • 20
    Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G, Gessain A, Harrington W, Panelatti G & Hermine O (2010) Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol 28, 41774183.
  • 21
    Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, Ikeda S, Masuda M, Nagoshi H, Ueda R et al. (2007) VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 25, 54585464.
  • 22
    Matsuoka M & Jeang KT (2007) Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 7, 270280.
  • 23
    Brown PH, Viner JL, Brewster A, Heckman CJ, Hursting S, Johnson K & Mao JT (2009) Conference report: Seventh Annual AACR International Conference on Frontiers in Cancer Prevention Research. Cancer Prev Res (Phila Pa) 2, 995998.
  • 24
    Beatty PL, Narayanan S, Gariepy J, Ranganathan S & Finn OJ (2010) Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer. Cancer Prev Res (Phila Pa) 3, 438446.
  • 25
    Kojima N, Biao L, Nakayama T, Ishii M, Ikehara Y & Tsujimura K (2008) Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity. J Control Release 129, 2632.
  • 26
    East L & Isacke CM (2002) The mannose receptor family. Biochim Biophys Acta 1572, 364386.
  • 27
    Narita M, Masuko M, Kurasaki T, Kitajima T, Takenouchi S, Saitoh A, Watanabe N, Furukawa T, Toba K, Fuse I et al. (2010) WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase. Int J Med Sci 7, 7281.
  • 28
    Kazanji M, Heraud JM, Merien F, Pique C, de The G, Gessain A & Jacobson S (2006) Chimeric peptide vaccine composed of B- and T-cell epitopes of human T-cell leukemia virus type 1 induces humoral and cellular immune responses and reduces the proviral load in immunized squirrel monkeys (Saimiri sciureus). J Gen Virol 87, 13311337.
  • 29
    Utsunomiya A, Miyazaki Y, Takatsuka Y, Hanada S, Uozumi K, Yashiki S, Tara M, Kawano F, Saburi Y, Kikuchi H et al. (2001) Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 27, 1520.
  • 30
    Tanosaki R, Uike N, Utsunomiya A, Saburi Y, Masuda M, Tomonaga M, Eto T, Hidaka M, Harada M, Choi I et al. (2008) Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome. Biol Blood Marrow Transplant 14, 702708.
  • 31
    Okamura J, Uike N, Utsunomiya A & Tanosaki R (2007) Allogeneic stem cell transplantation for adult T-cell leukemia/lymphoma. Int J Hematol 86, 118125.
  • 32
    Satou Y & Matsuoka M (2010) HTLV-1 and the host immune system: how the virus disrupts immune regulation, leading to HTLV-1 associated diseases. J Clin Exp Hematop 50, 18.
  • 33
    Furukawa Y, Osame M, Kubota R, Tara M & Yoshida M (1995) Human T-cell leukemia virus type-1 (HTLV-1) Tax is expressed at the same level in infected cells of HTLV-1-associated myelopathy or tropical spastic paraparesis patients as in asymptomatic carriers but at a lower level in adult T-cell leukemia cells. Blood 85, 18651870.
  • 34
    Harashima N, Kurihara K, Utsunomiya A, Tanosaki R, Hanabuchi S, Masuda M, Ohashi T, Fukui F, Hasegawa A, Masuda T et al. (2004) Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. Cancer Res 64, 391399.
  • 35
    Kannagi M, Harashima N, Kurihara K, Ohashi T, Utsunomiya A, Tanosaki R, Masuda M, Tomonaga M & Okamura J (2005) Tumor immunity against adult T-cell leukemia. Cancer Sci 96, 249255.
  • 36
    Lezin A, Gillet N, Olindo S, Signate A, Grandvaux N, Verlaeten O, Belrose G, de Carvalho Bittencourt M, Hiscott J, Asquith B et al. (2007) Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy/tropical spastic paraparesis patients. Blood 110, 37223728.
  • 37
    Macnamara A, Rowan A, Hilburn S, Kadolsky U, Fujiwara H, Suemori K, Yasukawa M, Taylor G, Bangham CR & Asquith B (2010) HLA class I binding of HBZ determines outcome in HTLV-1 infection. PLoS Pathog 6, el001117.
  • 38
    Shimizu Y, Yamakami K, Gomi T, Nakata M, Asanuma H, Tadakuma T & Kojima N (2003) Protection against Leishmania major infection by oligomannose-coated liposomes. Bioorg Med Chem 11, 11911195.
  • 39
    Kato C, Kajiwara T, Numazaki M, Takagi H & Kojima N (2008) Oligomannose-coated liposomes activate ERK via Src kinases and PI3K/Akt in J774A.1 cells. Biochem Biophys Res Commun 372, 898901.
  • 40
    Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA & Perarnau B (1997) HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 185, 20432051.
  • 41
    Senju S, Hirata S, Matsuyoshi H, Masuda M, Uemura Y, Araki K, Yamamura K & Nishimura Y (2003) Generation and genetic modification of dendritic cells derived from mouse embryonic stem cells. Blood 101, 35013508.
  • 42
    Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, Yokomine K, Harao M, Beppu T et al. (2006) Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 12, 26892697.
  • 43
    Kozako T, Fukada K, Hirata S, White Y, Harao M, Nishimura Y, Kino Y, Soeda S, Shimeno H, Lemonnier F et al. (2009) Efficient induction of human T-cell leukemia virus-1-specific CTL by chimeric particle without adjuvant as a prophylactic for adult T-cell leukemia. Mol Immunol 47, 606613.
  • 44
    Kozako T, Akimoto M, Toji S, White Y, Suzuki S, Arima T, Suruga Y, Matsushita K, Shimeno H, Soeda S et al. (2011) Target epitopes of HTLV-1 recognized by class I MHC-restricted cytotoxic T lymphocytes in patients with myelopathy and spastic paraparesis and infected patients with autoimmune disorders. J Med Virol 83, 501509.
  • 45
    Karanikas V, Lurquin C, Colau D, van Baren N, De Smet C, Lethe B, Connerotte T, Corbiere V, Demoitie MA, Lienard D et al. (2003) Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol 171, 48984904.
  • 46
    Aubry JP, Blaecke A, Lecoanet-Henchoz S, Jeannin P, Herbault N, Caron G, Moine V & Bonnefoy JY (1999) Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity. Cytometry 37, 197204.